The MESI-STRAT Consortium
15 Partners from seven European countries conribute to MESI-STRAT:
Jointly with modelers and experimentalists at the University of Newcastle, UK (Dr. Shanley) and the Charité in Berlin, Germany (Prof. Sers), work at the University of Innsbruck (Prof. Thedieck) focuses on oncogenic signaling through the mTOR and MAPK networks. Experimentalists and modelers at the German Cancer Research Center (DKFZ, Dr. Opitz), the University of Bergen, Norway (Prof. Ziegler), the University of Tromso, Norway (Prof. Heiland) and Neuroimmun GmbH, Karlsruhe, Germany (Dr. Kellner) focus on metabolic networks centered on tryptophan and NAD metabolism.
Model and data management and analyses are conducted by HITS, Heidelberg (PD Dr. Müller) and the University of Bergen (Dr. Grellscheid). PD-value B.V. (Elassaiss-Schaap, Tektemur-Altay) in Utrecht, The Netherlands customizes our models for the pharma sector.
Our computational models are developed, individualized, and validated based on patient derived in vitro and in vivo models from Dr. Serra (Vall d’Hebron Institute of Oncology, Barcelona, Spain) and Prof. van den Eynde (De Duve Institute, Brussels, Belgium), and patient samples from clinical trials within and associated with MESI-STRAT. The MESI-STRAT clinical trials are coordinated by the clinician scientist Dr. Opitz (DKFZ), and conducted by PATH Biobank (Dr. Anzeneder) and the Medical University Innsbruck
(Dr. Daniel Egle) supported by the University Hospital Heidelberg.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 754688.